CD44 and neoplasm: Our previous study has confirmed that the CD44-enriched extracellular matrix of trastuzumab-resistant tumors, such as those derived from JIMT-1 cells, creates a formidable barrier that shields the core region of tumor spheroids from antibody access and severely restricts trastuzumab-mediated cytotoxicity by NK cells [8].